This is in line with the values of T2D incidence almost reduced by half in N_ITA with respect to S_ITA [87] and may further support recent attention drawn by our best candidate gene (i.e., ADCY3) as a promising target for the development of anti-obesity drugs [88]. This evidence concerns the gene ADCY3 and obesity due to melanocortin 4 receptor deficiency.